Reneo Pharmaceuticals Management
Management criteria checks 4/4
Reneo Pharmaceuticals' CEO is Greg Flesher, appointed in Nov 2020, has a tenure of 3.5 years. total yearly compensation is $569.70K, comprised of 99% salary and 1% bonuses, including company stock and options. directly owns 0.069% of the company’s shares, worth $38.51K. The average tenure of the management team and the board of directors is 3 years and 3.4 years respectively.
Key information
Greg Flesher
Chief executive officer
US$569.7k
Total compensation
| CEO salary percentage | 99.0% |
| CEO tenure | 3.5yrs |
| CEO ownership | 0.07% |
| Management average tenure | 3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Oct 03
Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth
Apr 25Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Nov 22We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
Aug 09Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?
Apr 22We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth
Jan 20Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation
Oct 02Our First Look At Reneo Pharmaceuticals
Aug 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$570k | US$564k | -US$77m |
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$54m |
| Dec 31 2022 | US$1m | US$545k | -US$52m |
| Sep 30 2022 | n/a | n/a | -US$49m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$5m | US$475k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$529k | US$79k | -US$19m |
Compensation vs Market: Greg's total compensation ($USD569.70K) is about average for companies of similar size in the US market ($USD661.47K).
Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.
CEO
Greg Flesher (53 yo)
3.5yrs
Tenure
US$569,704
Compensation
Mr. Gregory J. Flesher, also known as Greg, serves as President, Director and Chief Executive Officer of Reneo Pharmaceuticals, Inc since November 2020. He had been Consultant of Eledon Pharmaceuticals, In...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.4yrs | US$215.13k | 1.48% $ 821.3k | |
| President | 3.5yrs | US$569.70k | 0.069% $ 38.5k | |
| Chief Medical Officer | 6.3yrs | US$466.23k | 0% $ 0 | |
| Chief Development Officer | 2.6yrs | US$447.10k | 0.041% $ 22.6k | |
| SVP of Finance & Administration and Principal Financial & Accounting Officer | no data | no data | 0.062% $ 34.2k | |
| Chief Operating Officer | 2.2yrs | US$781.47k | 0.073% $ 40.6k |
3.0yrs
Average Tenure
53yo
Average Age
Experienced Management: RPHM's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 6.4yrs | US$215.13k | 1.48% $ 821.3k | |
| President | 3.5yrs | US$569.70k | 0.069% $ 38.5k | |
| Independent Director | 6.4yrs | US$165.13k | 0% $ 0 | |
| Director | 6.4yrs | US$155.13k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$166.63k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$141.47k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$115.13k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$175.13k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$170.63k | 0% $ 0 |
3.4yrs
Average Tenure
50yo
Average Age
Experienced Board: RPHM's board of directors are considered experienced (3.4 years average tenure).